Payment overview · 2025
General Payments
$91.79
4 reported records · 4 companies
Healthcare provider profile · identity verified
William Brus, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · EUGENE, OR · NPI 1427007632
Verified facts
What the public records show
CMS Open Payments records show William Brus, M.D. received $91.79 in general payments during 2025 across 4 reported records.
Amgen Inc. accounted for 26.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 140 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 268 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $24.47 | 26.7% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $23.42 | 25.5% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $22.02 | 24.0% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.88 | 23.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $91.79 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $24.47 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $24.47 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $23.42 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $23.42 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $22.02 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $21.88 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 140 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
140 | 32 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
268 | 65 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 881 | 266 |
| Lisinopril | Lisinopril | 772 | 202 |
| Levothyroxine Sodium | Levothyroxine Sodium | 620 | 165 |
| Amlodipine Besylate | Amlodipine Besylate | 610 | 172 |
| Losartan Potassium | Losartan Potassium | 413 | 128 |
| Gabapentin | Gabapentin | 297 | 86 |
| Tamsulosin Hcl | Tamsulosin Hcl | 289 | 83 |
| Metoprolol Succinate | Metoprolol Succinate | 285 | 86 |
| Metformin Hcl | Metformin Hcl | 279 | 80 |
| Eliquis | Apixaban | 268 | 65 |
| Omeprazole | Omeprazole | 266 | 79 |
| Hydrochlorothiazide | Hydrochlorothiazide | 250 | 76 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 225 | 70 |
| Trazodone Hcl | Trazodone Hcl | 213 | 52 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 210 | 78 |
| Furosemide | Furosemide | 207 | 60 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 191 | 49 |
| Metoprolol Tartrate | Metoprolol Tartrate | 182 | 54 |
| Simvastatin | Simvastatin | 164 | 45 |
| Oxycodone Hcl | Oxycodone Hcl | 161 | 40 |
| Potassium Chloride | Potassium Chloride | 159 | 41 |
| Carvedilol | Carvedilol | 158 | 40 |
| Allopurinol | Allopurinol | 146 | 41 |
| Pravastatin Sodium | Pravastatin Sodium | 145 | 40 |
| Jardiance | Empagliflozin | 140 | 32 |
| Metformin Hcl Er | Metformin Hcl | 136 | 45 |
| Pantoprazole Sodium | Pantoprazole Sodium | 136 | 39 |
| Escitalopram Oxalate | Escitalopram Oxalate | 135 | 30 |
| Duloxetine Hcl | Duloxetine Hcl | 134 | 34 |
| Sertraline Hcl | Sertraline Hcl | 124 | 35 |
| Atenolol | Atenolol | 113 | 34 |
| Alendronate Sodium | Alendronate Sodium | 111 | 38 |
| Zolpidem Tartrate | Zolpidem Tartrate | 101 | 22 |
| Warfarin Sodium | Warfarin Sodium | 99 | 25 |
| Lovastatin | Lovastatin | 98 | 32 |
| Tramadol Hcl | Tramadol Hcl | 97 | 30 |
| Clopidogrel | Clopidogrel Bisulfate | 91 | 33 |
| Irbesartan | Irbesartan | 91 | 23 |
| Pioglitazone Hcl | Pioglitazone Hcl | 91 | 28 |
| Meloxicam | Meloxicam | 86 | 21 |
| Lorazepam | Lorazepam | 78 | 18 |
| Trulicity | Dulaglutide | 77 | 17 |
| Estradiol | Estradiol | 75 | 25 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 73 | 20 |
| Citalopram Hbr | Citalopram Hydrobromide | 72 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 66 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 66 | 21 |
| Glipizide | Glipizide | 64 | 17 |
| Baclofen | Baclofen | 63 | 13 |
| Spiriva Handihaler | Tiotropium Bromide | 62 | 12 |
| Ozempic | Semaglutide | 59 | 17 |
| Alprazolam | Alprazolam | 57 | 17 |
| Montelukast Sodium | Montelukast Sodium | 57 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 55 | 12 |
| Bupropion Xl | Bupropion Hcl | 50 | 12 |
| Ezetimibe | Ezetimibe | 50 | 16 |
| Famotidine | Famotidine | 49 | 16 |
| Morphine Sulfate Er | Morphine Sulfate | 48 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 47 | 11 |
| Bupropion Hcl Sr | Bupropion Hcl | 47 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 46 | 16 |
| Spironolactone | Spironolactone | 45 | 16 |
| Torsemide | Torsemide | 44 | 16 |
| Chlorthalidone | Chlorthalidone | 42 | 12 |
| Diphenhydramine Hcl | Diphenhydramine Hcl | 40 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 39 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 39 | 13 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 39 | 16 |
| Glimepiride | Glimepiride | 38 | 11 |
| Clonazepam | Clonazepam | 37 | 11 |
| Finasteride | Finasteride | 37 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 36 | 12 |
| Clonidine Hcl | Clonidine Hcl | 34 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 34 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 33 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 32 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 31 | suppressed |
| Prednisone | Prednisone | 31 | 28 |
| Diclofenac Sodium | Diclofenac Sodium | 30 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 30 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 30 | 21 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 30 | 26 |
| Valsartan | Valsartan | 30 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 29 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 28 | suppressed |
| Diazepam | Diazepam | 27 | suppressed |
| Lansoprazole | Lansoprazole | 26 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 26 | 11 |
| Ondansetron Hcl | Ondansetron Hcl/Pf | 26 | suppressed |
| Ramipril | Ramipril | 26 | suppressed |
| Acyclovir | Acyclovir | 25 | 14 |
| Pregabalin | Pregabalin | 25 | suppressed |
| Cephalexin | Cephalexin | 24 | 16 |
| Xarelto | Rivaroxaban | 24 | suppressed |
| Levetiracetam | Levetiracetam | 23 | suppressed |
| Topiramate | Topiramate | 23 | suppressed |
| Aripiprazole | Aripiprazole | 22 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 22 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 22 | suppressed |
| Lamotrigine | Lamotrigine | 22 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 22 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 22 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 22 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 21 | suppressed |
| Mirtazapine | Mirtazapine | 21 | suppressed |
| Ondansetron Odt | Ondansetron | 21 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 21 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 20 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 20 | 11 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 19 | suppressed |
| Glipizide Er | Glipizide | 19 | suppressed |
| Naproxen | Naproxen | 19 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 19 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 18 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 18 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 18 | suppressed |
| Celecoxib | Celecoxib | 17 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Memantine Hcl | Memantine Hcl | 17 | suppressed |
| Synthroid | Levothyroxine Sodium | 17 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 16 | suppressed |
| Telmisartan | Telmisartan | 16 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 15 | suppressed |
| Dutasteride | Dutasteride | 15 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 15 | suppressed |
| Buprenorphine | Buprenorphine | 14 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Januvia | Sitagliptin Phosphate | 14 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 14 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 14 | suppressed |
| Ramelteon | Ramelteon | 14 | suppressed |
| Temazepam | Temazepam | 14 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 13 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 13 | suppressed |
| Carbamazepine | Carbamazepine | 13 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 13 | suppressed |
| Methocarbamol | Methocarbamol | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 12 | 12 |
| Bupropion Hcl | Bupropion Hcl | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Sotalol | Sotalol Hcl | 12 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 12 | suppressed |
| Alyacen | Norethindrone-Ethin. Estradiol | 11 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $91.79 · 4 records | Amgen Inc. | AREXVY, JARDIANCE, OTEZLA, PAXLOVID, REPATHA, SHINGRIX | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error